194 related articles for article (PubMed ID: 28397817)
1. Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity.
Zhao X; Sun K; Lan Z; Song W; Cheng L; Chi W; Chen J; Huo Y; Xu L; Liu X; Deng H; Siegenthaler JA; Chen L
Sci Rep; 2017 Apr; 7():46344. PubMed ID: 28397817
[TBL] [Abstract][Full Text] [Related]
2. Update on tenofovir toxicity in the kidney.
Hall AM
Pediatr Nephrol; 2013 Jul; 28(7):1011-23. PubMed ID: 22878694
[TBL] [Abstract][Full Text] [Related]
3. In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue.
Mak LY; Liu SH; Yap DY; Seto WK; Wong DK; Fung J; Chan TM; Lai CL; Yuen MF
Dig Dis Sci; 2019 Dec; 64(12):3630-3641. PubMed ID: 31280390
[TBL] [Abstract][Full Text] [Related]
4. Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity.
Murphy RA; Stafford RM; Petrasovits BA; Boone MA; Valentovic MA
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257038
[TBL] [Abstract][Full Text] [Related]
5. In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.
Vidal F; Domingo JC; Guallar J; Saumoy M; Cordobilla B; Sánchez de la Rosa R; Giralt M; Alvarez ML; López-Dupla M; Torres F; Villarroya F; Cihlar T; Domingo P
Antimicrob Agents Chemother; 2006 Nov; 50(11):3824-32. PubMed ID: 16940060
[TBL] [Abstract][Full Text] [Related]
6. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.
Pushpakom SP; Liptrott NJ; Rodríguez-Nóvoa S; Labarga P; Soriano V; Albalater M; Hopper-Borge E; Bonora S; Di Perri G; Back DJ; Khoo S; Pirmohamed M; Owen A
J Infect Dis; 2011 Jul; 204(1):145-53. PubMed ID: 21628669
[TBL] [Abstract][Full Text] [Related]
7. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion.
Tanji N; Tanji K; Kambham N; Markowitz GS; Bell A; D'agati VD
Hum Pathol; 2001 Jul; 32(7):734-40. PubMed ID: 11486172
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors.
Venhoff N; Setzer B; Melkaoui K; Walker UA
Antivir Ther; 2007; 12(7):1075-85. PubMed ID: 18018766
[TBL] [Abstract][Full Text] [Related]
9. Renal toxicity associated with tenofovir use.
Rodriguez-Nóvoa S; Alvarez E; Labarga P; Soriano V
Expert Opin Drug Saf; 2010 Jul; 9(4):545-59. PubMed ID: 20384533
[TBL] [Abstract][Full Text] [Related]
10. HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D.
Liu Y; Miller MD; Kitrinos KM
Liver Int; 2014 Aug; 34(7):1025-32. PubMed ID: 24118725
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats.
Lebrecht D; Venhoff AC; Kirschner J; Wiech T; Venhoff N; Walker UA
J Acquir Immune Defic Syndr; 2009 Jul; 51(3):258-63. PubMed ID: 19582894
[TBL] [Abstract][Full Text] [Related]
12. Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
Lanier ER; Ptak RG; Lampert BM; Keilholz L; Hartman T; Buckheit RW; Mankowski MK; Osterling MC; Almond MR; Painter GR
Antimicrob Agents Chemother; 2010 Jul; 54(7):2901-9. PubMed ID: 20439609
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir renal toxicity targets mitochondria of renal proximal tubules.
Kohler JJ; Hosseini SH; Hoying-Brandt A; Green E; Johnson DM; Russ R; Tran D; Raper CM; Santoianni R; Lewis W
Lab Invest; 2009 May; 89(5):513-9. PubMed ID: 19274046
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.
Herlitz LC; Mohan S; Stokes MB; Radhakrishnan J; D'Agati VD; Markowitz GS
Kidney Int; 2010 Dec; 78(11):1171-7. PubMed ID: 20811330
[TBL] [Abstract][Full Text] [Related]
15. Absence of Neurofibromin Induces an Oncogenic Metabolic Switch via Mitochondrial ERK-Mediated Phosphorylation of the Chaperone TRAP1.
Masgras I; Ciscato F; Brunati AM; Tibaldi E; Indraccolo S; Curtarello M; Chiara F; Cannino G; Papaleo E; Lambrughi M; Guzzo G; Gambalunga A; Pizzi M; Guzzardo V; Rugge M; Vuljan SE; Calabrese F; Bernardi P; Rasola A
Cell Rep; 2017 Jan; 18(3):659-672. PubMed ID: 28099845
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy.
Perazella MA
Kidney Int; 2010 Dec; 78(11):1060-3. PubMed ID: 21076445
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir-induced toxicity in renal proximal tubular epithelial cells: involvement of mitochondria.
Milián L; Peris JE; Gandía P; Andújar I; Pallardó L; Górriz JL; Blas-García A
AIDS; 2017 Jul; 31(12):1679-1684. PubMed ID: 28650379
[TBL] [Abstract][Full Text] [Related]
18. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
Van Rompay KK; Durand-Gasselin L; Brignolo LL; Ray AS; Abel K; Cihlar T; Spinner A; Jerome C; Moore J; Kearney BP; Marthas ML; Reiser H; Bischofberger N
Antimicrob Agents Chemother; 2008 Sep; 52(9):3144-60. PubMed ID: 18573931
[TBL] [Abstract][Full Text] [Related]
19. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.
Miller MD; Margot NA; Lamy PD; Fuller MD; Anton KE; Mulato AS; Cherrington JM
J Acquir Immune Defic Syndr; 2001 Aug; 27(5):450-8. PubMed ID: 11511821
[TBL] [Abstract][Full Text] [Related]
20. The clinical and pathological features of adefovir dipivoxil-related renal impairment
.
Lv Y; Li X; Liang S; Liang D; Xu F; Zhu X; Zeng C
Clin Nephrol; 2019 Mar; 91(3):180-186. PubMed ID: 30614440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
